Elsevier

European Geriatric Medicine

Volume 5, Issue 6, December 2014, Pages 406-415
European Geriatric Medicine

Hot topic in geriatric medicine: EIP on AHA column
MACVIA-LR, Reference site of the European Innovation Partnership on Active and Healthy Ageing (EIP on AHA) in Languedoc Roussillon

https://doi.org/10.1016/j.eurger.2014.07.013Get rights and content

Abstract

The Région Languedoc-Roussillon is the umbrella organisation for an interconnected and integrated project on AHA covering the 3 pillars of the European Innovation Partnership on Active and Healthy Ageing. All sub-activities (A1: electronic pharmaceutical file, A2: falls prevention initiative, A3: frailty, B3: chronic respiratory diseases, chronic diseases with comorbidities, oral health and hepatitis virus C chronic infection, C2 and D4 active and independent living and handicap) are included in MACVIA-LR that has a strong political commitment and includes all stakeholders (public, private, patients, policy makers). It is one of the Reference Sites of the European Innovation Partnership on Active and Healthy Ageing built around chronic diseases, ageing and handicap. The framework of MACVIA-LR has the vision that the prevention and management of CDs is essential for AHA promotion and for the reduction of handicap. The main objective of MACVIA-LR is to develop innovative solutions for a network of Living Labs in order to improve the care of patients affected by CDs in the Languedoc-Roussillon area and to disseminate the innovation.

Introduction

The pilot European Innovation Partnership on Active and Healthy Ageing (EIP on AHA – http://www.webgate.ec.europa.eu/eipaha/) Strategic Implementation Plan has defined 3 priority areas of work and proposed a first set of 6 specific actions that were launched in 2012 (Table 1).

The Région Languedoc-Roussillon (LR) is the umbrella organization for an interconnected and integrated project on AHA, covering the 3 priority areas and Action Plans of the EIP on AHA [1]. The MACVIA-LR Reference Site of the EIP on AHA is built around CDs, ageing and handicap. It has a strong political commitment and includes all stakeholders (public, private, patients, policy makers).

MACVIA-LR has the vision that the prevention and management of chronic diseases (CDs) is essential for AHA promotion and for the reduction of handicap. The main objective of MACVIA-LR is to develop innovative solutions through a network of Living Labs in order to improve the care of patients affected by CDs in LR and to disseminate the innovation beyond.

MACVIA-LR follows the Living Labs definition of ENoLL (European Network of Living Labs) (http://www.openlivinglabs.eu): a real-life test and experimentation environment where users and producers co-create innovation, Public-Private-People Partnerships (PPPP) fostering user-driven open innovation. Research or clinical results can rapidly be deployed in real life for all users.

Two years after the launch of the call for EIP on AHA Reference Sites (February 28, 2012), a review of MACVIA-LR achievements is being provided to give an example of how the EIP on AHA was able to mobilize the stakeholders of a EU region in order to accomplish the goals of the partnership.

Section snippets

Governance

MACVIA-LR is under the leadership of the Fondation des Maladies Chroniques – Languedoc-Roussillon MACVIA. This abides by the rules of the Fondations Partenariales (Article L. L719-13 du Code de l’éducation http://www.universites-numeriques.fr), which follow the Code de l’éducation (Law no 87-571 of 23 July 1987, Decree no 91-1005 of 30 September 1991 to apply Law no 90-559 of 4 July 1990 and modify Law no 87-571 of 23 July 1987). The founding members of the Fondation Partenariale are the

MACVIA Living Labs in line with the EIP on AHA Action Plans

All MACVIA-LR Living Labs are transversal and integrated across the EIP on AHA Actions Plans. However, they are more related to a specific Action Plan (Table 3).

Eurobiomed

Eurobiomed is a non-for-profit organisation which has been accredited by the French government as a “competitive cluster”. There are 71 “competitive clusters” in France, and Eurobiomed is one of the eight Biotechnology – Pharma clusters. Eurobiomed federates healthcare stakeholders in both “Provence-Alpes-Côte d’Azur” and “Languedoc-Roussillon”. Dedicated real estate solutions and public sector support services are available for companies. Eurobiomed includes 400 companies with about 3000

Website

The MACVIA-LR website is hosted by the Région Languedoc-Roussillon and is available in English and French (http://macvia.cr-languedocroussillon.fr).

European Parliament (Brussels, November 2012)

A debate was held (13 November 2012) at the EU Parliament on the Impact of early diagnosis and control of chronic respiratory diseases on Active and Healthy Ageing (AHA) [35]. The debate was organised under the auspices of the Cyprus Presidency of the EU (2012) and represented a follow-up of the priorities of the Polish Presidency of the EU (2011) [22], [36].

Palais du Luxembourg (Paris, June 2013)

The EIP on AHA was presented in France at the Palais du Luxembourg, and the French reference sites and commitments for action were

Scaling up and transferability

Members of the LR region are already using the nine-step scaling up strategy of ExpandNet/WHO (WHO library, 2010, ISBN 978 92 4 150031 9) for:

  • •

    dissemination and advocacy;

  • •

    organisational process;

  • •

    cost/resource mobilisation and;

  • •

    monitoring and evaluation.

ExpandNet/WHO is a global network of public health professionals and scientists seeking to advance the practice and science of scaling up successful health innovations tested in experimental, pilot and demonstration projects.

Disclosure of interest

Bousquet J.: Scientific and advisory boards Actelion, Almirall, Meda, Merck, MSD, Novartis, Sanofi-Aventis, Takeda, Teva, Uriach.

Lectures during meetings – Almirall, AstraZeneca, Chiesi, GSK, Meda, Menarini, Merck, MSD, Novartis, Sanofi-Aventis, Takeda, Teva, Uriach.

Board of Directors – Stallergènes.

Camu W.: received honoraria for consulting activities and clinical research from Novartis, Sanofi, Actelion, Merck and Roche.

Costa P.: I am a consulting expert for the following pharmaceutical

References (37)

  • J. Bousquet et al.

    Birth cohorts in asthma and allergic diseases: Report of a NIAID/NHLBI/MeDALL joint workshop

    J Allergy Clin Immunol

    (2014)
  • M.E. Tinetti et al.

    The patient who falls: “It's always a trade-off”

    JAMA

    (2010)
  • A.J. Campbell et al.

    Implementation of multifactorial interventions for fall and fracture prevention

    Age Ageing

    (2006)
  • A.J. Campbell et al.

    Fall prevention: single or multiple interventions? Single interventions for fall prevention

    J Am Geriatr Soc

    (2013)

  • 2008–2013 Action plan for the global strategy for the prevention and control of non communicable diseases. Prevent and control cardiovascular diseases, cancers, chronic respiratory diseases, diabetes

    (2008)

  • European Union Health Policy Forum. Answer to DG SANCO consultation on chronic diseases

    (2012)
  • R. Busse et al.

    Tackling chronic disease in Europe. Strategies, interventions and challenges. European Observatory on Health Systems and Policies

    (2010)
  • J. Bousquet et al.

    System medicine approaches for the definition of complex phenotypes in chronic diseases and ageing. From concept to implementation and policies

    Curr Pharm Des

    (2014)

    • Cited by (0)

    1

    Deceased author.

    View full text
    Copyright © 2014 Published by Elsevier Masson SAS